Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Alembic Pharmaceuticals Ltd.
Change Company   
BSE Code 533573
ISIN Demat INE901L01018
Book Value 273.17
NSE Code APLLTD
Dividend Yield % 1.62
Market Cap 133486.02
P/E 28.24
EPS 24.05
Face Value 2  
10-Mar-2026 Alembic Pharmaceuticals incorporates subsidiary i...
10-Mar-2026 Alembic Pharmaceuticals surges on incorporating s...
06-Mar-2026 Alembic Pharmaceuticals informs about press relea...
26-Feb-2026 Alembic Pharma gets USFDA’s final approval for La...
26-Feb-2026 Alembic Pharmaceuticals informs about press relea...
24-Feb-2026 Alembic Pharma gets USFDA’s final approval for Ef...
19-Feb-2026 Alembic Pharmaceuticals receives two observations...
06-Feb-2026 Alembic Pharma gets USFDA’s approval for Carbidop...
05-Feb-2026 Alembic Pharmaceuticals reports marginal fall in ...
27-Jan-2026 Alembic Pharmaceuticals gets USFDA’s final approv...
27-Jan-2026 Alembic Pharmaceuticals informs about press relea...
12-Jan-2026 Alembic Pharmaceuticals gets USFDA’s tentative ap...
18-Dec-2025 Alembic Pharmaceuticals gets USFDA’s final nod fo...
18-Dec-2025 Alembic Pharmaceuticals informs about press relea...
11-Dec-2025 Alembic Pharma gets USFDA’s nod for Loteprednol E...
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.